| NCT ID | NCT05996653 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Low-grade Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-08-12 |
| Primary Completion | 2028-08-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-08-12 with a primary completion date of 2028-08-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Low grade gliomas (LGGs) are malignant, infiltrative and incurable brain tumours that typically present in the younger population. This project proposes to use non-contrast metabolic "Saturation Transfer" (ST)-MRI to evaluate LGG tumour progression and aims to predict early changes in LGG. Early identification of LGG patients whose tumours will progress will permit early interventions. ST-MRI does not involve any intravenous injection of contrast and which acquires metabolic information not seen by standard MRI.
Eligibility Criteria
Inclusion Criteria: 1. Be at least 12 years of age; 2. Diagnosed with: 1. Cohort A (pre-surgical): Suspected LGG (oligodendroglioma or astrocytoma), based on any combination of histological, molecular, radiological, and/or clinical findings; or 2. Cohort B (post-surgical): IDH1/2-mutant or IDH-wildtype (WT) low-grade glioma candidate for observation 3. No contraindications to MRI; 4. eGFR \> 30 ml/min; 5. No prior chemotherapy or radiation therapy; 6. No need for upfront treatment (surgery, chemotherapy, and/or radiation therapy) 7. Followed at either Sunnybrook Health Sciences Centre or at St Michael's Hospital Exclusion Criteria: 1. Need for upfront post-surgical treatment with either chemotherapy and/or radiation therapy 2. Pregnancy
Contact & Investigator
Greg J Stanisz, PhD
PRINCIPAL INVESTIGATOR
Sunnybrook Health Sciences Centre
Frequently Asked Questions
Who can join the NCT05996653 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Low-grade Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05996653 currently recruiting?
Yes, NCT05996653 is actively recruiting participants. Contact the research team at MaryJane.LimFat@sunnybrook.ca for enrollment information.
Where is the NCT05996653 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT05996653 clinical trial?
NCT05996653 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is Greg J Stanisz, PhD at Sunnybrook Health Sciences Centre. The trial plans to enroll 100 participants.